<DOC>
	<DOC>NCT02037737</DOC>
	<brief_summary>The purpose of this study is to assess Abatacept Intravenous (IV) effectiveness in patients with inadequate response to one or more conventional Disease Modifying Against Rheumatism (DMARDs) including Methotrexate in France, through the estimation of Abatacept retention rate over 2 years and reasons of discontinuation</brief_summary>
	<brief_title>Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting</brief_title>
	<detailed_description>Observational Model: Other: ReACTION is a study using secondary data originally collected in ACTION study. In ACTION, data were collected prospectively from October 2010 up to 2015 at each clinical visit. In France, data collection started in June 2011</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>All patients enrolled in ACTION with inadequate response to one or more conventional DMARDs including Methotrexate and treated with Abatacept IV will be included in ReACTION ACTION inclusion criteria for France were: Male or female subjects of more than 18 years old Patients with a diagnosis of established moderate to severe active RA Patients who at their physician's discretion are treated with Abatacept (initiated or already on treatment within 3 months) according to routine clinical practice Patients for whom baseline characteristics are available Patients consent for usage of their data in ACTION study Patients who were not included in any interventional clinical trial in RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>